2022-2023 Drug Updates in Solid Tumors

Area of Science:

• Oncology
• Pharmacology
• Clinical Practice

Background:

• The landscape of cancer therapeutics is rapidly evolving.
• Continuous education is crucial for advanced practitioners managing solid malignancies.
• Keeping abreast of regulatory approvals ensures optimal patient care.

Purpose of the Study:

• To summarize key US Food and Drug Administration (FDA) approvals for solid tumors.
• To provide advanced practitioners with essential information on new oncologic therapies.
• To highlight indications, mechanisms of action, and management strategies for novel treatments.

Main Methods:

• Review of US Food and Drug Administration (FDA) approvals for solid malignancies between late 2022 and late 2023.
• Presentation of new therapeutic agents, including their clinical indications.
• Discussion of mechanisms of action and practical guidance on monitoring and managing potential side effects.

Main Results:

• Key FDA-approved therapies for solid tumors were detailed.
• Information on indications, mechanisms of action, and side effect management was provided.
• Focus on practical application for advanced practitioners in clinical settings.

Conclusions:

• Advanced practitioners were updated on critical late 2022-2023 FDA approvals in solid tumor oncology.
• The information presented aids in the effective integration of new therapies into patient care.
• Understanding new treatments, their actions, and side effect profiles is vital for optimal patient outcomes.